GridAI Technologies Partners with IBN to Enhance Corporate Communications
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Strategic Partnership: GridAI Technologies has partnered with IBN to enhance its visibility among the public and investors through IBN's extensive investor network and social media channels, thereby increasing its market influence.
- Technology Integration: GridAI's software-driven control system coordinates electricity generation, storage, and demand in real-time, enabling large power users and utilities to economically optimize operations amidst fluctuating electricity loads, enhancing system flexibility and reliability.
- Market Demand Response: As electrification and electric vehicles proliferate, GridAI's intelligent energy orchestration solutions effectively address the volatility in power systems, meeting the challenges of dynamic demand in modern power environments and ensuring stable electricity supply.
- Brand Impact: With over 20 years of industry experience and more than 500 client partners, IBN leverages its distribution network of over 5,000 news outlets to provide GridAI with extensive exposure to investors and media, supporting its brand development.
Analyst Views on GRDX
About GRDX
GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
